In European Pharmaceutical Manufacturer’s June 2023 issue, Abzena’s Sr. Director of Cell Line Development, Nicole Wakes and VP of Cell Line Development, Simon Keen, were featured in an article entitled: “Cell line development strategies fit for a new era of Bispecific Antibodies”. In this piece, they outline the strategies that developers must consider to overcome the challenges of developing BsAbs under increasing pressure for speed.
Advances in biotechnologies using molecules of complexity — such as bispecific antibodies (BsAbs) — offer broad applications in many disease areas, including asthma, macular degeneration, arthritis, and Crohn’s disease. When considering the production of these new-era biologics, a clear strategy is needed from the outset.
Abzena’s Cell Line Development (CLD) Capabilities:
Our integrated approach to CLD enables us to streamline and de-risk the path to IND. We have developed multiple cell lines that have progressed from process development into manufacture and through clinical trials. With years of experience in cell line development (CLD), our team has successfully expressed biologics including antibodies, antibody fragments, bispecific antibodies, fusion proteins, growth factors and vaccines.
For molecules such as mAbs, Fabs and Fc fusions, we minimize timelines using our standard AbZelect™ platform methodology. For novel and complex molecules, our AbZelectPRO™ platform allows us to design and develop a rapid, robust approach to your program.
Click here to learn more about our CLD offering.